A5080034026- Receptor Mechanisms and Signaling
- Monoclonal and Polyclonal Antibodies Research
- Computational Drug Discovery Methods
- Protein Kinase Regulation and GTPase Signaling
- Advanced Proteomics Techniques and Applications
- Melanoma and MAPK Pathways
- NF-κB Signaling Pathways
- Cell Adhesion Molecules Research
- Cancer therapeutics and mechanisms
- Cancer, Hypoxia, and Metabolism
- Cytokine Signaling Pathways and Interactions
- HER2/EGFR in Cancer Research
- Cutaneous Melanoma Detection and Management
- Microtubule and mitosis dynamics
- Cancer-related Molecular Pathways
- Advanced Breast Cancer Therapies
- Medical Imaging Techniques and Applications
- Colorectal Cancer Treatments and Studies
- RNA and protein synthesis mechanisms
- Cancer Genomics and Diagnostics
- Microbial Inactivation Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Prostate Cancer Treatment and Research
- Advanced biosensing and bioanalysis techniques
- Radiopharmaceutical Chemistry and Applications
Pfizer (United States)
2005-2023
Constitutive activation of the epidermal growth factor receptor (EGFR) is prevalent in epithelial cancers, particularly non-small cell lung carcinoma (NSCLC). Mutations identified EGFR predict sensitivity to EGFR-targeted therapy. Detection these mutations mainly based on tissue biopsy, which invasive, expensive, and time consuming.Noninvasive, real-time, inexpensive detection monitoring patients with NSCLC highly desirable.We developed a novel core technology, electric field-induced release...
AG-012986 is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4/6, CDK5, and CDK9, with selectivity over diverse panel of non-CDK kinases. Here, we report the potent antitumor efficacies multiple tumor lines in vitro vivo. showed antiproliferative activities IC(50)s <100 nmol/L 14 18 cell lines. In vivo, significant efficacy induced by was seen (tumor growth inhibition, >83.1%) 10 11 human xenograft models when administered at or near maximum tolerated...
Clinical trials of selective RAF inhibitors in patients with melanoma tumors harboring activated BRAFV600E have produced very promising results, and a inhibitor has been approved for treatment advanced melanoma. However, about third developed resectable skin during the course trials. This is likely related to observations that activate extracellular signal-regulated kinase (ERK) signaling, stimulate proliferation, induce epithelial hyperplasia preclinical models. Because these findings raise...
<p>Individual MLAST curves and biomarker staining from G12C KP animals treated with vehicle, Compound A, sotorasib</p>
<p>Structure of Compound A</p>
<p>Compound A modulates glucose metabolism and pERK signaling in MiaPaCa2 tumors after 3 days of treatment the PET imaging cohort animals</p>
<p>G12C KP model survival data from long-term treatment with Compound A</p>
<p>Baseline differences in tumor progression and histopathology of G12D versus G12C KP GEM models</p>
<div>Abstract<p>KRAS is one of the most commonly mutated oncogenes in lung, colorectal, and pancreatic cancers. Recent clinical trials directly targeting KRAS G12C presented encouraging results for a large population non-small cell lung cancer (NSCLC), but resistance to treatment concern. Continued exploration new inhibitors preclinical models needed address mechanisms improve duration patient responses. To further enable development inhibitors, we present framework involving...
<p>Individual MLAST curves and biomarker staining from G12C KP animals treated with vehicle, Compound A, sotorasib</p>
<p>Baseline and post-treatment PET/CT images of individual KrasLSL-G12C/wtp53fl/fl animals treated with vehicle or Compound A</p>
<p>Baseline differences in tumor progression and histopathology of G12D versus G12C KP GEM models</p>
<p>Supplementary Methods Section</p>
<p>Compound A modulates glucose metabolism and pERK signaling in MiaPaCa2 tumors after 3 days of treatment the PET imaging cohort animals</p>
<p>G12C KP model survival data from long-term treatment with Compound A</p>
<p>Tolerability and individual MiaPaCa2 tumor growth data from animals treated with two weeks of Compound A</p>
<p>Structure of Compound A</p>
<p>Tolerability and individual MiaPaCa2 tumor growth data from animals treated with two weeks of Compound A</p>
<p>Supplementary Methods Section</p>
<p>Baseline and post-treatment PET/CT images of individual KrasLSL-G12C/wtp53fl/fl animals treated with vehicle or Compound A</p>